Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 14/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217389 | 0.90 | PKM (0.55) | PKMTP53GAAALDH1A1MEN1 | |
| SCHEMBL2301965 | 0.86 | ALDH1A1 (0.60) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL2301942 | 0.85 | MAPT (0.54) | PKMTP53GAAALDH1A1MEN1 | |
| SCHEMBL12353997 | 0.84 | LMNA (0.51) | PKMTP53GAAALDH1A1MEN1 | |
| SCHEMBL2302229 | 0.84 | HTR6 (0.47) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL2303199 | 0.83 | LMNA (0.53) | PKMTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL2304631 | 0.82 | LMNA (0.59) | TP53ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2300518 | 0.82 | MAPT (0.61) | PKMTP53ALDH1A1MEN1KMT2A | |
| SCHEMBL2300500 | 0.82 | KMT2A (0.52) | PKMTP53GAAMEN1KMT2A | |
| SCHEMBL14239653 | 0.81 | MAPT (0.47) | PKMGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| EP-2536693-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | Université Laval (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| WO-2011100840-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITé LAVAL (CA) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011100840-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITé LAVAL (CA) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | PKM 2928/4885TP53 26/4885GAA 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.